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Introduction
The tumor-node-metastasis (TNM) staging of non-small 
cell lung cancer (NSCLC) is crucial to determine the 
optimal treatment and predict the patient outcome. Among 
the TNM stages, T staging is determined based on various 
factors, including size, location, invasion, and satellite 
nodules (1-3). Moreover, according to the current lung 
cancer staging system (8th edition), T descriptor is divided 
and configured based on a 1-cm tumor size intervals (1).
However, N staging is relatively simpler, with just three 
stages: N1, N2, and N3. The TNM staging system (8th 
edition) recommends a more heterogeneous classification 
system, i.e., single station N1 (N1a) and multistation N1 
(N1b) involvement, and single station N2 involvement 
without N1 (N2a1), combined single station N2 and N1 
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(N2a2) involvement, and multistation N2 involvement 
(N2b).; however, such a system has not been adopted in 
clinical practice to date (4), which is likely due to the lack of 
studies on lymph node (LN) metastasis. To date, the status 
of metastatic LNs has not been well defined for lung cancer, 
unlike other solid cancers, such as prostate, colorectal, 
thyroid, or breast cancers (5-11). According to previous 
studies, the prognosis may be poor in the case of extranodal 
extension (EN) existence or large metastatic LN in these 
solid cancers. However, there lacks studies evaluating 
whether the severity of LN metastasis has an impact on the 
prognosis of patients with NSCLC (5-10). Therefore, the 
question of whether the severity of LN metastasis impacts 
the prognosis of patients remains unanswered.
Herein, we evaluated the impacts of the status of LN 
metastasis in patients with lung adenocarcinoma (ADC). We 
focused on two factors that are well established in other solid 
cancers: the metastatic lymph node size (MLNS) and EN.
This article was prepared referencing the Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) reporting checklist (available at http://dx.doi.
org/10.21037/jtd-20-2039).
Methods 
This study was conducted in accordance with the Declaration 
of Helsinki (as revised in 2013). As a retrospective study, 
patient consent was waived with the approval of our 
institutional review board (IRB number: NCC 2019-0064).
The patients’ records of 1,787 subsets who underwent 
pulmonary resection for lung ADC from October 2002 to 
December 2014 were retrospectively reviewed and analyzed. 
We investigated the following parameters via medical 
record, telephone surveillance, and the Korean National 
Health Insurance Service (NHIS) database: demographic, 
clinical, treatment, and pathologic characteristics of patients 
and follow-up data for survival. The included patients 
were those who underwent complete anatomical resection 
and mediastinal LN dissection for pathologic stage N1 
and N2 disease, and patients who received preoperative 
chemotherapy were excluded. Finally, 375 patients met the 
inclusion criteria were enrolled in the current analysis.
Histopathologic reviews
Patients included in this study underwent curative anatomic 
lung resection and systematic LN dissection (via lobectomy 
or greater, including bilobectomy and pneumonectomy). 
If LNs were positive, sections were cut and stained using 
hematoxylin and eosin (H&E); these stains were examined 
by a thoracic oncology pathologist (L.G.K). In this study, 
the definition of EN was the tumor extending into the 
perinodal fibrous-adipose tissue through the capsule of LN 
(Figure 1). MLNS was defined as the long-axis diameter of 
the largest metastatic focus of the metastatic LN.
Follow-up
During the first two years of the postoperative follow-
up period, surveillance was performed every 3 months; 
thereafter, surveillance was performed biannually and then 
annually after the fifth year. Recurrence was defined either 
by radiologic findings or histologic confirmation of a tumor. 
We defined overall survival (OS) as the period between the 
date of surgery and the date of death for any reason, and 
disease-free survival (DFS) as period between the date of 
surgery and the date of recurrence or death.
Statistical analysis
All statistical analyses were conducted using STATA 11.0 
software (StataCorp, College Station, TX). For comparisons 
between the groups, descriptive statistics were performed; a 
chi-square test or Fisher’s exact test was used for categorical 
variables, and Student’s t-test was used for continuous 
Figure 1 Histologic findings of lymph node metastasis in lung 
adenocarcinoma (hematoxylin and eosin; ×40) Arrows indicate 
extranodal extension of lymph node metastasis. The metastatic 
cells in the lymph node invaded through the nodal capsule into 
the perinodal fatty tissue. Metastatic lymph node size was defined 
as the long-axis diameter of the largest metastatic focus of the 
metastatic lymph node (bidirectional arrow).
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variables. The Kaplan-Meier method was used to estimate 
OS and DFS. Significant differences in prognostic factors 
were identified by log-rank tests. The effect of MLNS on 
survival was analyzed using logistic regression, and the 
maximal chi-square method was applied to examine a cutoff 
point of MLNS that divided patients into high- and low-risk 
groups (12,13). We determined the cutoff point for MLNS 
at 7 mm with a corrected P value of <0.001. The influence 
of significant prognostic factors from the multivariable 
model was estimated using the Cox proportional hazards 
analysis. The variables with a P value of less than 0.20 were 
included in the final Cox proportional hazards model. A 
two-sided P value less than 0.05 was considered to indicate 
statistical significance. A professional statistician reviewed 
and verified the statistical analysis.
Results
Clinicopathologic characteristics of patients according to 
MLNS and EN
The median follow-up period for the 375 patients was 
69.2 months, and the average number of dissected LNs was 
28.8±9.7. When patients were categorized into two groups 
according to the size of MLNS, the MLNS ≤7 mm group 
(n=169, 45.1%) and the MLNS >7 mm group (n=206, 
54.9%), a greater MLNS was associated with presence of 
EN (P<0.001), large tumor size (3.5±1.6 vs. 4.0±1.8 cm; 
P=0.015), and advanced N status (P<0.001, Table 1). Among 
the study patients, 212 patients (56.5%) were found to have 
EN. When these patients were classified into two groups 
stratified to the presence of EN, the EN-absence group 
(n=163) and the EN-presence group (n=212), EN was 
associated with large tumor size (3.5±1.6 vs. 4.0±1.7 cm; 
P=0.004), and large MLNS (P<0.001, Table 1).
Prognostic factors for survival
The potential prognostic factors including age, sex, 
operation type, visceral pleural invasion, tumor size, T 
stage, N stage, MLNS, presence of EN, and adjuvant 
chemotherapy were evaluated in the study. Multivariable 
Cox proportional hazards model showed that tumor size 
Table 1 Clinicopathological characteristics of patients according to the size of metastatic lymph nodes and the presence of extranodal extension
Variables
MLNS EN
>7 mm (n=206) ≤7 mm (n=169) P value EN (+) (n=212) EN (–) (n=163) P value
Age, years 58.9±11.1 60.9±9.6 0.075 60.1±10.6 59.4±10.4 0.521
Sex, male 116 (56.3%) 86 (50.9%) 0.295 116 (54.7%) 86 (52.8%) 0.706
Tumor size, cm 4.0±1.8 3.5±1.6 0.015 4.0±1.7 3.5±1.6 0.004
VPI (+) 123 (61.7%) 97 (55.0%) 0.195 123 (58.0%) 97 (59.5%) 0.771
Pneumonectomy 10 (4.9%) 7 (4.1%) 0.945 14 (6.6%) 3 (1.8%) 0.080
T stage 0.597 0.120
T1 38 (18.4%) 38 (22.5%) 38 (17.9%) 38 (23.3%)
T2 142 (68.9%) 109 (64.5%) 141 (66.5%) 110 (67.5%)
T3 26 (12.6%) 22 (13.0%) 33 (15.6%) 15 (9.2%)
N stage <0.001 0.251
N1 66 (32.0%) 94 (55.6%) 85 (40.1%) 75 (46.0%)
N2 140 (68.0%) 76 (44.4%) 127 (50.9%) 88 (54.0%)
EN (+) 154 (74.8%) 58 (34.3%) <0.001
MLNS >7 mm 154 (72.6%) 52 (31.9%) <0.001
Adjuvant 
chemotherapy
137 (66.5%) 120 (71.0%) 0.350 140 (66.0%) 117 (71.8%) 0.235
MLNS, size of metastatic lymph nodes; VPI, visceral pleural invasion; EN, extranodal extension.
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[hazard ratio (HR) 1.135, 95% confidence interval (CI): 
1.050 to 1.228, P=0.001], adjuvant chemotherapy (HR 
0.582, 95% CI: 0.430 to 0.787, P<0.001), presence of EN 
(HR 1.454, 95% CI: 1.029 to 2.055, P=0.034), and MLNS 
greater than 7 mm (HR 1.741, 95% CI: 1.238 to 2.447, 
P=0.001) were independent poor prognostic factors for 
survival (Table 2). MLNS was also a significant risk factor 
for survival when it was considered as a continuous variable 
and the 7 mm cutoff was not employed (HR 1.045, 95% CI: 
1.022 to 1.069, P<0.001).
Survival curves according to MLNS and presence of EN
Significant difference found between the survival curves for 
the MLNS ≤7 mm and MLNS >7 mm groups (P<0.001, 
Figure 2A). Moreover, there was also a significant difference 
between the OS curves for the EN-presence and EN-
absence groups (P<0.001, Figure 2B). Patients were 
categorized into 3 subgroups: Group A, MLNS ≤7.0 mm/
EN (−); Group B, MLNS ≤7.0 mm/EN (+) or MLNS 
>7.0 mm/EN (−); and Group C, MLNS > 7.0 mm/EN 
(+). The 5-year OS was 72.2%, 59.0%, and 38.5% in 
Groups A, B and C, respectively (P<0.001, Figure 3A). The 
5-year DFS was 43.5%, 31.3%, and 18.4% in Groups A, 
B and C, respectively (P<0.001, Figure 3B). There were 
160 patients with N1 metastasis and 215 patients with 
N2 metastasis, and the subgroup analyses were conducted 
in these subsets. Among N1 patients (n=160), significant 
difference was found between the survival curves for the 
MLNS ≤7 mm group and MLNS >7 mm group (P=0.023, 
Figure 4A) and between the EN-presence and EN-absence 
groups (P=0.004, Figure 4B). Among N2 patients (n=215), 
significant difference was identified between the survival 
curves for the MLNS ≤7 mm group and MLNS >7 mm 
group (P<0.001, Figure 4C), as well as between the EN-
presence and EN-absence groups (P<0.001, Figure 4D).
Discussion
In this study, MLNS and EN were significantly correlated 
with large tumor size and advanced N status. Moreover, 
significant independent prognostic factors for survival were 
identified to be MLNS >7 mm and presence of EN, along 
with the TNM staging system. When we stratified the 
analysis by N1 and N2 status, patients with MLNS >7 mm 
and presence of EN had a worse survival rate than those 
with MLNS ≤7 mm and no presence of EN, regardless of 
nodal status.
At present, the T staging system involves a very careful 
classification based on tumor size, location, location, 
Table 2 Prognostic factors for overall survival in patients with lymph node metastasis
Variables
Univariate analysis (Log-rank test) Multivariable analysis (Cox hazards model)





Tumor size, cm <0.001 1.135 (1.050–1.228) 0.001
T stage (T1) 0.076
T2
T3
N stage (N1) <0.001
N2 
EN (+) <0.001 1.454 (1.029–2.055) 0.034
MLNS >7 mm <0.001 1.741 (1.238–2.447) 0.001
Adjuvant chemotherapy <0.001 0.582 (0.430–0.787) <0.001
HR, hazard ratio; CI, confidence interval; VPI, visceral pleural invasion; EN, extranodal extension; MLNS, size of metastatic lymph nodes.
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invasion, and satellite nodules (3,14,15). However, despite 
a description of the heterogeneous situation, N staging 
is relatively simple; it is classified as N0, N1, N2, and N3 
based on LN involvement (3). However, to date, there 
has been a number of studies evaluating the status of LN 
metastasis in other cancers, including gastric, colorectal, 
prostate, breast, and penile cancers, highlighting the 
importance of MLNS and EN (6-11,16,17).
In this study, MLNS was divided based on cutoff value 
of 7 mm (>7 or ≤7 mm). Based on the maximal chi-square 
test, MLNS >7 mm was determined to be an important 
prognostic factor with statistical significance. Although 
the method of measuring the size of MLNs—specifically, 
whether the measurement should reflect the gross LN size 
or the size of metastatic foci—remains controversial in the 
literature, this conundrum may be irrelevant in cases of 
lung ADC, since it is possible for anthracosis, tuberculosis, 
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in this study, we measured the diameter of true on a 
microscope after LN sectioning. We found that in patients 
with N1 and N2 stage disease, patients with MLNS >7 mm 
showed a much worse prognosis than those with MLNS 
≤7 mm. We believe that this result may be attributable to 
the greater tumor burden and/or disease severity in those 
with MLNS >7 mm. Even without dichotomization, when 
MLNS was analyzed as a continuous variable, MLNS was a 
meaningful prognostic factor (P<0.001).
Lee and colleagues (18) reported that NSCLC patients 
with EN had a poor prognosis, regardless of the degree 
of LN involvement. In addition, other studies have also 
shown an association of EN with increased risk of all-cause 
mortality and disease recurrence (22,23). Similarly, this 
study showed that cases with EN showed a much worse 
prognosis than those without EN for patients with N1 
and N2 stage disease. We believe that the presence of EN 
indicates a severe degree of regional LN involvement, with 
simultaneous vascular and lymphatic invasion. This suggests 
that EN can indicate tumor severity. Therefore, systemic 
LN dissection should be carried out by excising all potential 
structures that may contain tumor, including LNs and 
surrounding adipose tissue within the anatomic landmarks.
To date, the efficacy of adjuvant chemotherapy for 
stage II or III NSCLC has been well proven (24). Based 
on the current guidelines, the adjuvant chemotherapy is 
Figure 4 Overall survival curves of N1 patients stratified according to the MLNS (A) and presence of EN (B), and N2 patients according to 
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recommended in N1 or N2 disease, regardless of the status 
of LN metastasis, MLNS or EN. Since a considerable 
number of candidates for adjuvant therapies choose to 
drop out from the recommended treatments, the clinicians 
might be encouraged to recommend adjuvant therapy more 
strongly for node-positive patients with large MLNS or 
EN according to our study. At our institution, only 68.5% 
of patients with a good general postoperative performance 
status received adjuvant chemotherapy following complete 
resection. To improve survival and achieve better outcomes, 
patients with risk factors outlined in this study—presence of 
EN or MLNS >7 mm—should be monitored and observed 
more cautiously while pursuing more aggressive adjuvant 
treatments during the follow-up period.
While most operated lung cancer patients can be 
followed-up every 6 to 12 months postoperatively according 
to the surveillance guidelines (25,26), it might be reasonable 
to adopt a more frequent follow-up strategy (27), i.e., every 
3 months for the first 2 years and biannually thereafter, 
for patients with the presence of EN or MLNS >7 mm. 
The status of LN metastasis might be considered in the 
LN staging system for more accurate prediction of patient 
prognosis in the future.
Some of the limitations of our study are as follows. First, 
because this study is a single institutional retrospective 
study, confounding factors may have influenced the result. 
However, we tried to reduce the bias through additional 
subgroup analysis based on N1 and N2 disease. Second, 
there was no cross-validation with other independent patient 
groups, though our analysis was supported by statistical 
techniques, such as the maximal chi-square method. 
Conclusions
In conclusion, MLNS and presence of EN could provide 
an important prognostic implication for patients with node-
positive lung ADC. To improve the prognostic predictions 
and treatment decisions based on the LN staging system, 
an evaluation of the pathologic role of MLNS and EN in 
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